Your browser (Internet Explorer 7 or lower) is out of date. It has known security flaws and may not display all features of this and other websites. Learn how to update your browser.

X

Navigate / search

Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research (R01)

Key Dates: 
  • Posted Date: February 26, 2015
  • Open Date (Earliest Submission Date): May 5, 2015
  • Letter of Intent Due Date(s): Not Applicable
  • Application Due Date(s): Standard dates , by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  • AIDS Application Due Date(s): Standard AIDS dates apply, by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  • Scientific Merit Review: Standard dates apply or Month(s) Year(s)
  • Advisory Council Review: Standard dates apply or Month(s) Year(s)
  • Earliest Start Date: Standard dates apply or Month Year
Purpose: 

The purpose of this funding opportunity announcement (FOA) is twofold: 1. to accelerate translational and clinical Phase I and II a/b safety and efficacy studies for substantiating measurable functional benefits of probiotic/prebiotic components and/or their combinations; and; 2. to understand the underlying mechanisms of their action(s), and variability in responses to these interventions. This FOA calls for interdisciplinary collaborations across scientific disciplines engaged in microbiome and pro/prebiotic research including, but not limited to: nutritional science, microbiology, virology, microecology and microbiome, genomics, immunology, computational biology, chemistry, bioengineering, as well as integration of omics and computational approaches in DNA technologies. This FOA will not support phase III clinical trials.

Expiration Date: 
Tuesday, May 8, 2018
Announcement Number: 
PA-15-127